Cronos Group Inc vs Palantir Technologies Inc — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while Palantir Technologies Inc trades at $134.5 (market cap $320.57B). The key difference: Palantir Technologies Inc is far larger — about 314.3× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| CRON | PLTR | |
|---|---|---|
Market Cap | $1.02B | $320.57B |
Sector | Health | Technology |
52-Week High | $3.27 | $207.18 |
52-Week Low | $1.95 | $107.27 |
Enterprise Value | $203.29M | $312.75B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
PLTR trades at $130.05, up 2.57% today, with technical indicators showing neutral signals amid bearish moving averages. The company demonstrates exceptional fundamental strength with 2025 revenue of $4.48B and net income of $1.63B, representing a 36.3% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.33 surpassing the $0.28 estimate. Analyst consensus remains positive with a $185.75 price target, though valuation metrics remain elevated at P/E of 146.11 and P/S of 63.97.
PLTR presents a growth opportunity with strong AI positioning and expanding profitability, but faces significant valuation risk and competitive pressures. The stock's premium multiples require sustained high growth to justify current levels, while upcoming Q2 2026 earnings on August 3 will be critical for validating the growth trajectory. Institutional sentiment remains divided with 46% buy ratings versus 42% hold recommendations.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →